On this page

What the treatment aims to do

Stereotactic radiosurgery, or SRS, delivers focused radiation to the AVM target with the aim of causing the abnormal vessels to close over time. Despite the word “surgery,” it does not remove the nidus through an open resection. Planning uses detailed imaging to define the target and its relationship to surrounding brain tissue. Equipment names identify delivery systems, not proof that one method is best for every lesion.1

The effect is delayed

Obliteration may develop over years rather than at the moment radiation is delivered. During this latency period the AVM may still bleed. A completed treatment session is therefore different from confirmed disappearance of the shunt, and the time between them belongs in the benefit–harm discussion. The expected response and interim risk depend on the particular lesion and clinical context.1

For a previously ruptured AVM, concern about another hemorrhage during latency has a different context from preventive treatment of an unruptured lesion. An acute hemorrhage needs emergency assessment and stabilization; radiosurgery planning does not replace that immediate care. The choice of SRS should explain why its delayed effect is acceptable in the proposed plan.1

Selection and evidence

Target size, geometry, location, proximity to important tissue and prior treatment influence the feasibility and tradeoffs. Some lesions have features that make open surgery less attractive; that alone does not make radiation risk-free. Observation, surgery, embolization and combinations may remain part of a multidisciplinary discussion.1

The ISRS guidance examined Spetzler-Martin grade I–II AVMs. It reports a role for SRS in selected lesions, but most underlying data are observational and selection differs from surgical series. Surgical grade also has limitations when used to predict SRS outcomes. These findings do not establish superiority for every low-grade lesion or for all higher grades.2

ARUBA's randomized findings concern medical management versus a mixture of interventions in adult unruptured AVMs, not a head-to-head radiosurgery trial. Any proposed radiation treatment still requires an explanation of its expected benefits, procedural and delayed harms, alternatives and evidence limits.3

Adverse effects and incomplete response

Focused delivery reduces exposure outside the target but does not guarantee that all normal brain tissue is spared. Radiation-related changes may cause swelling or neurological symptoms, and some effects can be delayed. Hemorrhage before obliteration and failure to achieve complete obliteration are also outcomes that need discussion. A favorable imaging response cannot by itself show preserved function or seizure freedom.421

If embolization is proposed before SRS, ask what it changes about the target and the overall plan. SNIS describes uncertainty about adjunctive embolization's role with SRS; previous procedures can affect imaging and target definition. A combined plan should explain the expected benefit and added risks of each stage.1

Questions about confirmation and follow-up

Ask how the team will monitor for adverse effects and determine whether the shunt has disappeared. Ask what a residual nidus would mean and when another treatment might be considered. MRI/MRA and catheter angiography have different roles, and the confirmation method matters when comparing published obliteration results.1

References

  1. De Leacy R et al. J NeuroIntervent Surg. 2022;14:1118–1124. doi:10.1136/neurintsurg-2021-018632. Source ↩
  2. Graffeo CS et al. Neurosurgery. 2020;87:442–452. doi:10.1093/neuros/nyaa004. Source ↩
  3. Mohr JP et al. Lancet Neurol. 2020;19:573–581. doi:10.1016/S1474-4422(20)30181-2. PubMed ↩
  4. Mayo Clinic Staff. Stereotactic radiosurgery. Patient information. Source ↩